Upstaza™, the first direct-administered gene therapy into the brain, was approved in the EU and UK for AADC deficiency patients. Unaudited net product revenue of $535 million in 2022 representing 25% ...
Event to take place on Dec. 2, 2025 in New York City WARREN, N.J., Nov. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host an R&D Day to discuss its ...
San Diego-based Tang Capital Management added 400,000 PTC Therapeutics shares in the third quarter. The value of the position increased by $38.3 million quarter over quarter. Tang Capital reported ...
We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. PTC Therapeutics, Inc. is one of them. PTC Therapeutics, Inc. (NASDAQ:PTCT) is a biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results